Chemo-Immunotherapy Side Effects in Patients with Breast Cancer Referred to Outpatient Clinics in Tehran, Iran
-
Majid Mesgartehrani
,
Zeinab Mesgartehrani
,
Zahra Bakhtiari
,
Mohammad Shakouri
,
Alireza Saadat
,
Mostafa Ghanei
,
Dariush Norozian
,
Mohammad Mesgartehrani
,
Maryam Shabany
Abstract
No Abstract
1. Roshandel G, Ghanbari-Motlagh A, Partovipour E, et al (2019). Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry. Cancer Epidemiology, 61:50-58.
2. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006). Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. Journal of the National Cancer Institute, 98:1108-1117.
3. Zheng X, Li S, Jie J (2021). Progress of researches on Fasciola and fascioliasis in Yunnan Province. Chinese Journal of Schistosomiasis Control, 33:317.
4. Pusztai L, Esteva FJ (2006). Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Investigation, 24:187-191.
5. Cortes J, Montero AJ, Glück S (2012). Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treatment Reviews, 38:143-151.
6. Montemurro F, Mittica G, Cagnazzo C, et al (2016). Self-evaluation of adjuvant chemotherapy-related adverse effects by patients with breast cancer. JAMA Oncology, 2:445-452.
2. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC (2006). Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. Journal of the National Cancer Institute, 98:1108-1117.
3. Zheng X, Li S, Jie J (2021). Progress of researches on Fasciola and fascioliasis in Yunnan Province. Chinese Journal of Schistosomiasis Control, 33:317.
4. Pusztai L, Esteva FJ (2006). Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Investigation, 24:187-191.
5. Cortes J, Montero AJ, Glück S (2012). Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treatment Reviews, 38:143-151.
6. Montemurro F, Mittica G, Cagnazzo C, et al (2016). Self-evaluation of adjuvant chemotherapy-related adverse effects by patients with breast cancer. JAMA Oncology, 2:445-452.
| Files | ||
| Issue | Vol 51 No 8 (2022) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijph.v51i8.10282 | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Mesgartehrani M, Mesgartehrani Z, Bakhtiari Z, Shakouri M, Saadat A, Ghanei M, Norozian D, Mesgartehrani M, Shabany M. Chemo-Immunotherapy Side Effects in Patients with Breast Cancer Referred to Outpatient Clinics in Tehran, Iran. Iran J Public Health. 2022;51(8):1909-1911.
